While amyloid plaques have been traditionally viewed as upstream events in the AD pathological cascade, recent studies have suggested that amyloid deposition, particularly when evaluated alongside tau markers, may provide a more comprehensive view of disease progression [29, 46, 92]. This evidence concerns the gene MAPT and Alzheimer disease.